The Re-Emergence of Device Reprocessing
The single-use device reprocessing and remanufacturing market is an estimated $200+ million business and growing fast thanks to cost containment pressures and the waning of early controversy surrounding the practice. By nearly any measure--including the number of facilities, number of approved products, and dollars both spent and saved--the SUD reprocessing industry is making a noteworthy impact on health care delivery in the US.
You may also be interested in...
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.
Announcing product milestones and liking LinkedIn posts are just some of the topics addressed in a long-awaited guidance that deals with the challenges prescription drug makers face in the UK when using social media.
Stakeholders suggest a variety of USPTO and FDA actions that could help ensure patents do not improperly delay generic and biosimilar competition.